logo-loader

Ergomed chosen to conduct growth hormone study

Published: 23:10 25 Jun 2015 AEST

Boffin
Macrilen has the potential to provide a much needed tool for the evaluation of AGHD

Ergomed (LON:ERGO) shares moved closer to their 52-week high after the company was chosen to conduct a clinical trial by Æterna Zentaris.

The UK provider of specialised services to the pharmaceutical industry has been chosen by the Canadian firm to manage the new, confirmatory phase III clinical study to demonstrate the efficacy of Macrilen, a novel orally-active small molecule that stimulates the secretion of growth hormones.

The study will be conducted as a two-way crossover study with the insulin tolerance test as the benchmark comparator, Ergomed told investors.

The study population will consist of patients with a medical history documenting risk factors for adult growth hormone deficiency (AGHD), running the gamut from those with a low risk of having AGHD to those with a high risk of having the condition.

A delighted Miroslav Reljanovic, chief executive officer of Ergomed, said the company has a strong working relationship with Æterna.

Ergomed is committed to developing orphan drugs, and we believe that Macrilen has the potential to provide a much needed tool for the evaluation of AGHD,” he said.

David Dodd, chairman, president and chief executive officer of Æterna, said he had great confidence in Ergomed’s ability to conduct the clinical study on schedule and within budget.

Ergomed's performance as our clinical research organisation supporting our pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer has been excellent,” Dodd said.

Ergomed’s shares rose 4.5p to 172p, and are up 11% year-to-date.

Ergomed Plc adds to co-development pipeline with Allergy Therapeutics deal

Andrew Mackie, chief business officer at Ergomed Plc (LON:ERGO), caught up with Proactive to discuss their co-development agreement with Allergy Therapeutics plc (LON:AGY). Under the terms of the collaboration, Ergomed will take the treatments for dust mite, tree pollen and grass pollen...

on 14/12/17